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Nosocomial infection caused by carbapenem-resistant Acinetobacter bauman-
nii (CRAB) has created a public health concern all around the world. In this study,
100 isolates of CRAB from hospitalized patients during 2015–2016 at Imam
Khomeini Hospital were investigated to determine the rates of multidrug-resistant
(MDR) and extensively drug-resistant (XDR) strains using Kirby–Bauer disk diffu-
sion method. The minimum inhibitory concentrations (MICs) of six antibiotics were
determined by broth microdilution method. Multiplex polymerase chain reaction
(PCR) was performed to detect blaOXA-51 like and blaOXA-58 like, blaOXA-23 like, and
blaOXA-24 like that are encoding resistance to carbapenems. All CRAB isolates were
MDR and XDR and 2% of them were pandrug-resistant (PDR), whereas colistin,
polymyxin B, and tigecycline were the most effective agents. All isolates were positive
for blaOXA-51 like by PCR. The frequency of blaOXA-23 like and blaOXA-24 like was 81%
and 22%, respectively. Findings of this study showed that very few therapeutic options
remained for the treatment of CRAB infections and blaOXA-23 like is a dominant
resistance gene in CRAB at this hospital.
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Introduction
Acinetobacter baumannii (A. baumannii) is one of the major hospital-
associated and an opportunistic pathogen that causes serious diseases in respira-
tory tract, bloodstream, urinary tract, at surgical site, and wound infections [1].
Acinetobacter spp. have intrinsic resistance to many antibiotics and disinfectants
due to low permeability of outer cell membrane and expression of efﬂux pumps;
furthermore, it can survive for long period of time on hospital inanimate surfaces
and equipment [2]. The Infectious Diseases Society of America expressed that
A. baumannii is one of the six antimicrobial-resistant pathogens that are respon-
sible for high morbidity and mortality in patients. Multidrug-resistant (MDR)
strains of A. baumannii (resistant to at least three different classes of antimicrobial
agents, such as cephalosporins, aminoglycosides, and ﬂuoroquinolones) emerged
in the last 2 decades [1].
Carbapenems are the drug of choice for MDR strains of A. baumannii
because of their potent bactericidal activity against them [3]. However,
A. baumannii develops resistance to carbapenems in all over the world with
different mechanisms, such as decreased permeability, altered penicillin-binding
proteins or porins (33-kDa CarO protein) that are causing an inﬂux channel for
carbapenems and overexpression of efﬂux pumps. Carbapenem-hydrolyzing
class D β-lactamases (CHDLs) and class B carbapenemase production are
important carbapenem-resistant mechanisms. The CHDLs (OXA carbapene-
mases) of Acinetobacter spp. have ﬁve phylogenetic subgroups: blaOXA-51 like,
blaOXA-58 like, blaOXA-23 like, blaOXA-24/40 like, and blaOXA-143 like [3–9]. The
blaOXA-51 like gene is an intrinsic gene for A. baumannii strains, however,
alone blaOXA-51like gene cannot represent the increase of carbapenem resistance,
because insertion of ISAba1 or similar IS elements is required in A. baumannii to
gain the carbapenem resistance [10]. Scotland was the ﬁrst where blaOXA-23 like
gene was characterized and after that the outbreak of this gene has been reported
from many countries, such as Bulgaria, People’s Republic of China, Brazil, Iran,
Iraq, Afghanistan, and French Polynesia. In many studies, the relationship
between the presence of blaOXA-23 like and resistance to imipenem and mer-
openem has been demonstrated [11].
The frequency of carbapenem-resistant Acinetobacter baumannii (CRAB) at
the hospitals of the United States varies from 33% to 58% [1] and infections
caused by these organisms have only limited number of therapeutic options [8]. In
cases with CRAB, the physician must use more toxic agent, such as colistin, a
cationic peptide antibiotic that becomes active drug in the blood [12–14].
However, clinical isolates of A. baumannii have acquired resistance to colistin
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more recently. The US hospitals in a surveillance study reported that the rate of
colistin resistance among Acinetobacter spp. is 5.3% [15]. Disturbance of the
electrostatic interactions between positively charged colistin molecules and the
negatively charged lipopolysaccharide of bacterial membrane reduces the activity
of colistin [13]. This study described the frequency of CRAB during a 9-month
study and investigated the susceptibility of them to other antibiotics. Furthermore,
the presence of blaOXA-23 like, blaOXA-24 like, blaOXA-51 like, and blaOXA-58 like
genes was investigated with multiplex polymerase chain reaction (PCR) to
determine the relationship between the presence of these genes and resistant to
carbapenems.
Materials and Methods
Isolation and identiﬁcation of CRAB
A. baumannii isolates were collected from blood, wound, urine, sputum, and
respiratory tract at different wards of Imam Khomeini Hospital in Tehran from
September 2015 to June 2016. The primary identiﬁcation of A. baumannii isolates
was carried out by biochemical tests [16]. One hundred of A. baumannii isolates that
were resistant to imipenem and meropenem were randomly collected as CRAB, and
then stored in trypticase soy broth and glycerol at −70 °C until use [17].
Antimicrobial susceptibility analysis
The susceptibility of CRAB isolates, to determine MDR and extensively
drug-resistant (XDR) and pandrug-resistant (PDR) phenotypes, was performed
using Kirby–Bauer disk diffusion method according to the CLSI guidelines
[18, 19] to various classes of antibiotics, such as gentamicin (10 μg), amikacin
(30 μg), ampicillin (10 μg), ampicillin/sulbactam (20 μg), trimethoprim/sulfa-
methoxazole (25 μg), piperacillin/tazobactam (100/10 μg), tetracycline (30 μg),
ticarcillin (75 μg), ticarcillin/clavulanic acid (75/10 μg), tobramycin (10 μg),
netilmicin (30 μg), cefepime (30 μg) cefotaxime (30 μg), ceftazidime
(30 μg), ceftriaxone (30 μg), ciproﬂoxacin (5 μg), levoﬂoxacin (5 μg), oﬂoxacin
(5 μg), meropenem (10 μg), imipenem (10 μg), doripenem (10 μg), doxycycline
(30 μg), minocycline (30 μg), tigecycline (10 μg), colistin (10 μg), polymyxin B
(300 units) (MAST, Merseyside, UK) [19]. The CRABs that were non-
susceptible to at least one agent in all but two or fewer antimicrobial categories
and the isolates that were resistant to all available antibacterial agents except
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polymyxin B and colistin were called XDR and PDR, respectively [17, 19, 20].
Minimum inhibitory concentrations (MICs) of imipenem, meropenem, colistin,
amikacin, cefotaxime, and ampicillin/sulbactam were determined using broth
microdilution method. Escherichia coli ATCC 25922 and Pseudomonas
aeruginosa ATCC 27853 were used as control strains [1, 18].
Multiplex PCR for evaluation of blaOXA genes
Multiplex PCR was carried out to detect blaOXA-51 like, blaOXA-23 like,
blaOXA-24 like, and blaOXA-58 like that are encoding carbapenem-resistance genes
using the primers described by Woodford et al. [8].
A. baumannii strains including NCTC 13304, NCTC 13302, NCTC 12156,
and NCTC 13305 were used as positive controls for blaOXA-23 like, blaOXA-24 like,
blaOXA-58 like, and blaOXA-51 like, respectively [18]. The multiplex PCR protocol
was the same as described by Woodford et al. [8].
Results
During the 9-month study period starting from September 2015, alto-
gether 3,731 clinical specimens were referred to the Imam Hospital Laboratory
for bacteriology tests and were positive in culture, of these 536 yielded
A. baumannii.
The prevalence of MDR and CRAB phenotypes among all isolates of
A. baumannii during the study was 83% (n= 445) and 80% (n= 429), respec-
tively. The randomly selected isolates in this study (n= 100) were recovered from
patients at ICUs (n= 43), emergency (n= 35), surgical wards (n= 7), and medical
(n= 15). The highest numbers of specimens belonged to ICUs. The blaOXA-51 like
was observed in all 100 CRAB isolates.
As shown in Table I, tracheal aspirates (n= 44) were the most clinical
specimens referred to the laboratory followed by blood (n = 38). About 58% of
patients were males and 42% were females. Table II shows the antibiotic
resistance pattern. Two isolates showed PDR phenotype, but all of them were
MDR and XDR (100%). The most effective antimicrobial agents were colistin
and polymyxin with two and ﬁve resistant strains, respectively. Tigecycline
(69%), minocycline (49%), and doxycycline (40%) were also effective anti-
biotics. MIC50 and MIC90 values of A. baumannii isolates are shown in Table III.
Colistin and ampicillin/sulbactam had the lowest MIC values. Imipenem
and amikacin and cefotaxime and meropenem had the highest MIC values,
respectively (Table III).
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The frequency of blaOXA-23 like and blaOXA-24 like was 81% and 22%,
respectively. The blaOXA-58 like gene was not found at CRAB isolates. The
coexistence of blaOXA-23 like and blaOXA-24 like was 19% (Figure 1).
Table I. Distribution of A. baumannii isolates that is
collected from different clinical specimens
Specimen Number
Blood 38
Urine 9
Tracheal aspirates 44
Pulmonary secretion 4
Wound 1
Catheter 1
Table II. Resistance range of A. baumannii isolates to various
antimicrobial agents
Antibiotics Sensitive Intermediate Resistant
Gentamicin 1 0 99
Tobramycin 7 1 92
Amikacin 1 0 99
Netilmicin 8 2 90
Imipenem 0 0 100
Meropenem 0 0 100
Doripenem 0 0 100
Ciproﬂoxacin 1 0 99
Levoﬂoxacin 19 22 59
Oﬂoxacin 2 3 95
Piperacillin/tazobactam 0 1 99
Ticarcillin 0 0 100
Ticarcillin/clavulanic acid 0 0 100
Cefotaxime 1 0 99
Ceftriaxone 0 0 100
Ceftazidime 2 1 97
Cefepime 0 0 100
Trimethoprim/
sulfamethoxazole
2 1 97
Ampicillin 0 1 99
Ampicillin/sulbactam 2 6 92
Colistin 98 0 2
Polymyxin B 95 – 5
Tetracycline 18 11 71
Doxycycline 40 2 58
Minocycline 49 9 42
Tigecycline 69 29 2
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Discussion
The results of bacteriology showed high prevalence of infections with MDR
and XDR strains of A. baumannii at different wards of Imam Khomeini Hospital.
The mortality rates of nosocomial infections with A. baumannii at the US hospitals
have been reported between 19% and 54% [20]. In this study, 536 isolates of
A. baumannii isolates were cultured and 90% of them were resistant to carba-
penems. Among the CRAB isolates, 100 were further investigated. The identiﬁ-
cation of isolates was conﬁrmed by PCR as all of them were positive for
blaOXA-51 like. Turton et al. [10] in 2006 demonstrated that detection of
blaOXA-51 like gene is a reliable method for identiﬁcation of A. Baumannii. Similar
ﬁndings were also reported from Iran [20].
Table III. The MIC50 and MIC90 values of A. baumannii isolates
Antibiotics MIC50 (μg/ml) MIC90 (μg/ml) Range (μg/ml) Mode (μg/ml)
Imipenem 1,280 1,280 0.625–1,280 1,280
Meropenem 80 320 0.625–1,280 40
Cefotaxime 640 1,280 0.625–1,280 640
Amikacin 1,280 1,280 0.625–1,280 1,280
Colistin 0.3 0.83 0.15625–1,280 0.16
Ampicillin/sulbactam 80 160 0.625–1,280 80
Figure 1. Multiplex PCR of A. baumannii isolates: blaOXA-51like (353 pb), blaOXA-23 like (501 bp),
blaOXA-24 like (246 bp), and blaOXA-23 like (599 bp)
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The majority of isolates recovered in this study were cultured from patients at
ICU, which is similar to the previous report from Iran from 2010 to 2012 in the
western regions of Iran [21]. The mortality rates for infections caused by CRAB have
been reported as 46% by Sheng et al. [22]. Patients hospitalized at ICUs in Asian and
European countries more likely to get infection with resistant A. baumannii isolates
than patients in the United States [23]. In this study, the respiratory tract of patients
was the main organ that CRAB caused infection. This is similar to results reported by
Sohail et al. [16] in Pakistan in 2016. Lee et al. [24] expressed that prolonged use of
mechanical ventilators in ICU probably causes the stability of CRAB, leading the
CRAB isolates as predominant bug in the respiratory tract.
In the last years, carbapenems were the choice for treatment against MDR
A. baumannii. However, the extreme use of these antibiotics has converted them as
resistant organism to various antibiotics. Higgins et al. [25] in 2009 showed that
among the 515 A. baumannii, 471 isolates were resistant to imipenem, 21 were
intermediate, and 23 were susceptible.
This study demonstrated that the annual incidence of CRAB has increased
during 2014–2016. In Hong Kong, the rate of CRAB increased from 2.6% in 1997
to 29.4% in 2008 [26]. The rate of imipenem-resistant Acinetobacter in a Spanish
hospital changed from 0 in 1991 to 50% in 2001 [27]. The global increase rate for
imipenem-resistant Acinetobacter during 2000–2004 is 40% [16]. In this study,
the MIC50 and MIC90 values for imipenem were 1,280. The MIC50 and MIC90 for
meropenem were 80 and 320, respectively.
Based on the results of this study, the CRAB isolates were resistant to the
majority of tested antibiotics. A signiﬁcant increase in antimicrobial resistance has
occurred worldwide from 2004 to 2009 [23]. In this study, 100% of CRAB was
MDR and XDR. Therefore, the resistance rates of A. baumannii in this study were
99% against piperacillin/tazobactam, gentamicin, amikacin, ciproﬂoxacin and 98%
to ampicillin/sulbactam and 97% against ceftazidime and trimethoprim/sulfameth-
oxazole, and 92% to tobramycin (85%). In a study from Spain conducted in 2014,
all CRAB isolates were found resistant to piperacillin/tazobactam, gentamicin,
imipenem, meropenem, doripenem, and ciproﬂoxacin, and majority of them were
not susceptible to trimethoprim/sulfamethoxazole (95%), tobramycin (85%), ami-
kacin (80%), and ampicillin/sulbactam (70%). In the same study, 50% and 20%
were not susceptible to minocycline and tigecycline, respectively [13].
Colistin, polymyxin B, and tigecycline are the only available antimicrobial
agents against the CRAB [29]. This study showed polymyxin B and tigecycline
are effective against CRAB. In Turkey, tigecycline has a potent effect on MDR
A. baumannii [29]. Colistin has more effect on the CRAB, but two isolates of
CRAB were resistance to colistin in this study. This means that CRAB can acquire
resistance to colistin. Maraki et al. [2] showed an increase of 7.9% resistance to
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colistin during 2010–2014. Previous exposure of CRAB to colistin is important
factor for acquiring resistance to this drug [13].
Combination therapy against infection with the CRAB is probably a good
choice, for example, the bactericidal effect of polymyxin combined with tigecy-
cline, rifampicin, or meropenem to XDR A. baumannii was promising [30].
Colistin combination with other agents, such as tigecycline, ampicillin/sulbactam,
rifampin, and carbapenems, is a good combination for CRAB treatment. García-
Quintanilla et al. [13] in 2014 observed lower mortality among patients who
received colistin and carbapenem and ampicillin/sulbactam together compared
with other regimens.
In this study, the blaOXA-23 like and blaOXA-24 like genes were abundant among
the isolates (81% and 22%, respectively). Although we have previously found
blaOXA-58 like gene in another study [20]; however, none of the isolates in this study
contained this gene. In China, theMDR A. baumannii contained the blaOXA-23 like and
blaOXA-58 like genes with the frequencies of 73% and 2%, respectively [26]. In India,
Vijayakumar et al. [31] in 2016 demonstrated the blaOXA-51 like and blaOXA-23 like
among all the 103 studied CRAB isolates. There is a relationship between the
existence of blaOXA-23 like and resistance of A. baumannii to carbapenems [16]. In
Brazil, CRAB is generally associated with carbapenemase production of blaOXA-23
that is also reported in other countries [28]. In accordance with results of this study,
the stewardship programs including molecular typing of bacteria should be performed
to strengthen infection control to prevent further dissemination of CRAB.
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